RxDoctor Payments Data

Noelle Loconte, MD

Medical Oncology · Madison, WINPI 1972568269

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,575 of the $4,075 with a category attached, or 87.7%. AbbVie accounts for 87.7% of it on its own, with 1 other manufacturer making up the rest.

$4,075in general payments, 2019–2025

Across 2 payments — averaging $2037.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Personal Genome Diagnostics Inc$500
$154,583in research payments, 2019–2025

Across 28 payments — averaging $5520.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Exact Sciences$57K
  • Bristol Myers Squibb$43K
  • Merck$30K
  • Taiho Oncology, Inc.$25K

What the payments were for

  • Consulting fees$3,57588%
  • Speaking & faculty fees$50012%

General payments by program year

20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie1$3,575
Personal Genome Diagnostics Inc1$500

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,075 in reported general payments places this provider in the 70th percentile of 54 medical oncology providers in Wisconsin.

See all medical oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$27,288
Medicare patients
119
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$23,718
Oxycodone Hcl21$453
Dexamethasone31$368
Ondansetron Hcl38$337
Prochlorperazine Maleate12$193
Duloxetine Hcl24$169
Pantoprazole Sodium13$159
Amlodipine Besylate23$66

Paid to pharmacies, not to this prescriber.

Other medical oncology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →